Bristol-Myers' Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)
Shots:
- The CHMP (EMA) recommendation is based on P-II CA180-372 (NCT01460160) study assessing Sprycel + CT in pediatric patients with newly diagnosed +ve acute lymphoblastic leukemia (ALL)
- Sprycel received the US FDA’s and EU’s approval to treat pediatric patients with +ve chronic myeloid leukemia in chronic phase (CML-CP) in Nov- 2017 & July- 2018 respectively
- Sprycel is a tyrosine kinase inhibitor- approved by the US FDA for philadelphia chromosome +ve CML-CP for adults
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
